

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 1 097 924 B1**

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
**25.08.2004 Bulletin 2004/35**

(51) Int Cl.7: **C07D 211/52, A61K 31/4409,  
A61P 25/04**

(21) Application number: **00123487.1**

(22) Date of filing: **07.11.2000**

(54) **4-hydroxy-4-phenylpiperidine derivatives having opioid agonist activity and pharmaceuticals containing the same**

4-Hydroxy-4-phenylpiperidine-Derivate mit opioid agonistischer Aktivität und diese enthaltende Pharmazeutika

Dérivés de la 4-hydroxy-4-phenylpiperidine ayant une activité agoniste opioïde et médicaments les contenant

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR**

(30) Priority: **08.11.1999 JP 31688199**

(43) Date of publication of application:  
**09.05.2001 Bulletin 2001/19**

(73) Proprietor: **SSP Co., Ltd.  
Chuo-ku, Tokyo 103-8481 (JP)**

(72) Inventors:

- Mogi, Kinichi  
Narita-shi, Chiba 286-0036 (JP)
- Kanamaru, Yoshihiko  
Narita-shi, Chiba 276-0033 (JP)
- Kawamoto, Noriyuki  
Narita-shi, Chiba 286-0036 (JP)
- Komoto, Teruo  
Chiba-shi, Chiba 263-0002 (JP)
- Umehara, Norimitsu  
Tokorozawa-shi, Saitama 359-0025 (JP)

- Sato, Susumu  
Narita-shi, Chiba 286-0011 (JP)
- Oka, Tetsuo  
Hiratsuka-shi, Kanagawa 286-0011 (JP)

(74) Representative: **Hartz, Nikolai F., Dr. et al  
Wächtershäuser & Hartz  
Patentanwälte  
Weinstrasse 8  
80333 München (DE)**

(56) References cited:  
**WO-A-97/09973**

- NOZAKI-TAGUCHI N ET AL:  
"CHARACTERIZATION OF THE  
ANTIHYPERALGESIC ACTION OF A NOVEL  
PERIPHERAL MU-OPIOID RECEPTOR AGONIST  
- LOPERAMIDE"  
ANESTHESIOLOGY,US,AMERICAN SOCIETY  
OF ANESTHIOLOGISTS, PHILADELPHIA, PA.,  
vol. 90, no. 1, 1999, pages 225-234, XP000910052  
ISSN: 0003-3022

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**:P 1 097 924 B1**

**Description****Technical Field**

- 5 [0001] The present invention relates to 4-hydroxy-4-phenylpiperidine derivatives excellent in peripheral analgesic action or salts thereof; and pharmaceuticals containing the same.

**Background Art**

- 10 [0002] As an analgesic, known are central opioid analgesics typified by morphine, non-steroidal anti-inflammatory drugs (NSAIDs) typified by indomethacin and local anesthetics typified by lidocaine [The Journal of Medicinal Chemistry, 42(9), 1481(1999) and cited references described therein].
- [0003] Morphine however cannot be used freely because of its undesirable central side effects. In addition, there are pains against which neither non-steroidal anti-inflammatory drugs nor local anesthetics have sufficient analgesic effects. There is accordingly a demand for the development of a medicament which is safer and has higher analgesic effects than them.
- 15 [0004] In recent years, existence of a  $\mu$ -receptor at the periphery has been revealed and analgesic action via this receptor has come to be elucidated [The Journal of Pharmacology and Experimental Therapeutics, 248(3), 1269(1989); The Journal of Investigative Dermatology, 111, 297(1988); and Drug Therapy, 323, 1685(1995)].
- 20 [0005] In Japanese Patent Application Laid-Open No. Sho 47-173, described are diarylpiperidinobutylamide compounds and among them, loperamide developed as a stegnotic is under development as a peripheral analgesic [Anesthesiology, 90, 225(1999); The Journal of Pharmacology and Experimental Therapeutics, 289, 494(1999)].
- [0006] The peripheral analgesic action of loperamide is however not always satisfactory.
- [0007] An object of the present invention is therefore to provide a compound excellent in peripheral analgesic action.
- 25

**Disclosure of the Invention**

- [0008] With the foregoing in view, the present inventors have carried out an extensive investigation to obtain a compound having excellent peripheral analgesic action. As a result, it has been found that a 4-hydroxy-4-phenylpiperidine derivative represented by the below-described formula (1) is markedly superior to the above-described loperamide in peripheral analgesic action and is therefore useful as a medicament, leading to the completion of the present invention.
- 30 [0009] In one aspect of the present invention, there is thus provided a 4-hydroxy-4-phenylpiperidine derivative as defined by claim 1, or a salt thereof; and a medicament containing it or its salt as an effective ingredient.
- [0010] In another aspect of the present invention, there is also provided a pharmaceutical composition containing the above-described 4-hydroxy-4-phenylpiperidine derivative or salt thereof and a pharmaceutically acceptable carrier.
- 35 [0011] In a further aspect of the present invention, there is also provided use of the above-described 4-hydroxy-4-phenylpiperidine derivative or salt thereof as a medicament.
- [0012] In a still further aspect, there is also provided a paint treating method, which comprises administering the above-described 4-hydroxy-4-phenylpiperidine derivative or salt thereof.
- 40


**Best Mode for Carrying out the Invention**

- [0013] Examples of the  $C_{1-6}$  alkyl group as  $R^1$  or  $R^2$  in the formula (1) of the invention compound (1) include linear or branched  $C_{1-6}$  alkyl groups, more specifically, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, tert-butyl, n-pentyl and n-hexyl groups. As the cycloalkyl group,  $C_{3-8}$  ones are preferred. Specific examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl groups. Among them, hydrogen atom and  $C_{1-6}$  alkyl groups are particularly preferred as each of  $R^1$  and  $R^2$ .
- 45 [0014]  $R^1$  and  $R^2$  together with the adjacent nitrogen atom may form a pyrrolidine ring.
- [0015] Examples of the  $C_{1-6}$  alkyl group as  $R^4$  or  $R^5$  include linear or branched  $C_{1-6}$  alkyl groups, more specifically, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, tert-butyl, n-pentyl and n-hexyl groups. As  $R^4$  or  $R^5$ , a hydrogen atom is preferred.
- 50 [0016] Examples of the  $C_{1-6}$  alkyl group as  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$  or  $R^{10}$  include linear or branched  $C_{1-6}$  alkyl groups, more specifically, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, tert-butyl, n-pentyl and n-hexyl groups. As the cycloalkyl group,  $C_{3-8}$  ones are preferred. Specific examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl groups.
- 55 [0017] The number of the member of the heterocyclic ring formed by  $R^7$  and  $R^8$  together with the adjacent nitrogen atom is 5 to 8. Examples of such a ring include pyrrolidine, piperidine, piperazine and morpholine rings. As  $R^6$ , hydrogen atom and  $C_{1-6}$  alkyl groups (particularly, ethyl) are preferred, while as  $R^9$ , hydrogen atom and  $C_{1-6}$  alkyl groups (par-

particularly, methyl) are preferred. As  $R^{10}$ ,  $C_{1-6}$  alkyl groups, particularly, methyl group is preferred.  $n$  stands for 1 to 6, of which 1 to 3 is preferred. No particular limitation is imposed on the salt of the invention compound (1) insofar as it is a pharmaceutically acceptable salt thereof. Examples include addition salts of an inorganic acid such as hydrochloric acid, sulfuric acid, hydrobromic acid or phosphoric acid and addition salts of an organic acid such as formic acid, acetic acid, fumaric acid, maleic acid or tartaric acid. The invention compounds also embrace solvates such as hydrates.

[0018] Each of the 4-hydroxy-4-phenylpiperidine derivatives and salts thereof according to the present invention can be prepared, for example, by any one of the following (Process A) to (Process C).

(Process A)





[wherein, X represents a halogen atom, and  $R^1$  and  $R^2$  have the same meanings as described above].

[0019] Described specifically, Invention compound (1a) is available by reacting Compound (1) with Compound (2). This reaction is usually conducted in the presence of 2 to 5 equivalents, preferably 3 equivalents of a base at 40 to 100°C, preferably 50 to 60°C for 1 to 3 hours. This reaction can be conducted in an anhydrous solvent such as benzene, toluene, tetrahydrofuran or dimethylformamide. Examples of the base include inorganic bases such as sodium carbonate and sodium hydroxide and organic bases such as triethylamine.

[0020] Each of Compound (1) and Compound (2) can be synthesized in a known manner.

## (Process B)





[wherein, n stands for 1 to 6, and R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup>, R<sup>5</sup>, X and Y have the same meanings as described above].

[0021] Described specifically, Invention compound (1b) is available by reacting Compound (1a) with Compound (3). This reaction is usually conducted in the presence of 1 to 3 equivalents, preferably 1 to 1.5 equivalents of a base at 20 to 100°C, preferably 20 to 60°C for 2 to 36 hours. This reaction can be conducted in an anhydrous solvent such as acetone, tetrahydrofuran, dimethylformamide or dimethylsulfoxide. Examples of the base include inorganic bases such as sodium carbonate, sodium hydroxide and sodium hydride and organic bases such as triethylamine. The base may be added together with potassium iodide.

[0022] Compound (3) is commercially available as a reagent easily or can be synthesized in a known manner.

## (Process C)



[wherein,  $R^1$ ,  $R^2$  and  $n$  have the same meanings as described above].

[0023] Described specifically, Invention compound (1d) is available by hydrolyzing Compound (1c) (Compound (1b) wherein  $R^4$ ,  $R^5 = H$ , and  $Y = OAc$ ) which has been synthesized by Process (B). This reaction is usually conducted in the presence of 1 to 3 equivalents, preferably 1 to 1.5 equivalents of a base at 20 to 40°C, preferably 20 to 25°C for 1 to 5 hours. This reaction can be conducted in a water miscible solvent such as methanol, ethanol, dioxane or tetrahydrofuran. Examples of the base include inorganic bases such as sodium hydroxide, potassium hydroxide and sodium carbonate.

[0024] A salt of Invention Compound (1) is available, for example, by reacting Compound (1) with 1 to 2 equivalents, preferably 1 to 1.2 equivalents of an acid in an anhydrous solvent at 0 to 30°C for 0.1 to 0.5 hour. Preferred examples of the solvent include anhydrous ether, anhydrous tetrahydrofuran, anhydrous chloroform, anhydrous dioxane and anhydrous acetone. As the acid, the above-exemplified ones can be employed.

[0025] Invention compound (1) or salt thereof thus obtained can be purified by using ordinary methods such as column chromatography and recrystallization in combination.

[0026] Invention compound (1) or salt thereof exhibits excellent  $\mu$ -opioid agonist action as described later in Tests and is therefore useful as a peripheral analgesic for animals including human being. The peripheral analgesic of the present invention can be used for the suppression or prevention of pain in various diseases (ex. various inflammatory diseases including arthritis and cancer), after operation, or in injury, fracture or burn.

[0027] Invention compound (1) or salt thereof, together with a pharmaceutically acceptable carrier, can be formed into a pharmaceutical composition of various dosage forms in a conventional manner. No particular limitation is imposed on the administration form and it can be selected as needed depending on the treating purpose. For example, administration can be conducted through any one of an orally dosable agent, injection, suppository, ointment and plaster. Such administration forms can each be manufactured in a manner known to those skilled in the art.

[0028] An orally dosable solid preparation such as tablet, coated tablet, granule, powder or capsule can be prepared by adding, to Invention compound (1), an excipient and if necessary, binder, disintegrator, lubricant, colorant, taste corrigent and smell corrigent and then treating the resulting mixture in a conventional manner.

[0029] An orally administrable liquid preparation such as a liquid preparation for internal use, syrup or elixir can be prepared by adding, to Invention compound (1), a taste corrigent, buffer, stabilizer or smell corrigent and then treating the resulting mixture in a conventional manner.

[0030] An injection such as subcutaneous, intramuscular or intravenous injection can be prepared by adding, to Invention compound (1), a pH regulator, buffer, stabilizer, isotonicizing agent or local anesthetic agent and then treating the resulting mixture in a conventional manner.

[0031] A suppository can be prepared by adding, to Invention compound (1), a pharmaceutical carrier known to those

skilled in the art, for example, polyethylene glycol, lanolin, cacao butter or fatty acid triglyceride and if necessary, a surfactant and then treating the resulting mixture in a conventional manner.

[0032] An ointment can be prepared by incorporating an ordinarily employed base material, stabilizer, humectant, preservative or the like as needed, and mixing them in a conventional manner.

[0033] A plaster may be prepared by applying the above-described ointment, or cream, gel, paste or the like, each made in a respective conventional manner, to an ordinarily employed backing material in a conventional manner.

[0034] The amount of Invention compound (1) to be incorporated in each of the above-described dosage forms differs depending on the conditions of the patient to be administered or the dosage form. In general, it is desired to incorporate it in an amount of about 0.25 to 100 mg for an orally dosable preparation, about 0.05 to 20 mg for an injection and about 0.1 to 50 mg for a suppository. The daily dose of the medicament in the above-described dosage form cannot be determined in a wholesale manner, because it differs with the symptom, body weight, age, sex, etc. of the patient. Usually, the daily dose may be about 0.005 to 2 mg/kg, preferably about 0.01 to 0.1 mg/kg per adult. It is desired to conduct administration once or in 2 to 4 portions a day.

## Examples

[0035] The present invention will hereinafter be described in detail by examples. It should however be borne in mind that the present invention is not limited to or by them.

### Referential Example 1

[0036] 4-Bromo-2,2-diphenylbutyric acid 23 g (72 mmol) was suspended in 150 mL of chloroform. At room temperature, 20 mL (270 mmol) of thionyl chloride was added dropwise to the resulting suspension. After addition of 0.2 mL of dimethylformamide, the resulting mixture was heated under reflux for 4 hours. After completion of the reaction, the solvent was concentrated under reduced pressure, whereby 23 g (yield: 94.7%) of 4-bromo-2,2-diphenylbutyric chloride was obtained.

[0037] In 100 mL of water were suspended 8 g (90 mmol) of a 50% aqueous solution of dimethylamine and 18 g (170 mmol) of sodium carbonate, followed by cooling to 0 to 5°C. A solution obtained by dissolving 23 g (68 mmol) of the 4-bromo-2,2-diphenylbutyric chloride mentioned above in 100 mL of toluene was then added dropwise. After stirring for 2 hours, the water layer taken out from the reaction mixture was washed with toluene. The resulting water layer was extracted with chloroform. The extract was washed with water and then dried. The residue obtained by concentrating the solvent under reduced pressure was crystallized from methyl isobutyl ketone, whereby 11 g (yield: 46.8%) of dimethyl(tetrahydro-3,3-diphenyl-2-furylidene)ammonium bromide was obtained.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ(ppm): 7.40-7.60(10H,m), 4.85(2H,t), 3.83(3H,s), 3.47(2H,t), 2.96(3H,s).

### Referential Example 2

[0038] To 30 mL of anhydrous tetrahydrofuran was added 940 mg (39 mmol) of magnesium powder. The one-fifth of a solution obtained by dissolving 10 g (38 mmol) of 2-benzyloxybromobenzene in 30 mL of anhydrous tetrahydrofuran was added. To the resulting mixture were added 0.1 mL of 1,2-dibromoethane and a small amount of iodine, followed by heating to 60 to 70°C. When the reaction started, the remaining portion of the anhydrous tetrahydrofuran solution of 2-benzyloxybromobenzene was added dropwise and the mixture was heated to reflux for further 30 minutes. In the resulting anhydrous tetrahydrofuran solution of Grignard reagent, 7 g (37 mmol) of 1-benzyl-4-piperidone dissolved in 30 mL of anhydrous tetrahydrofuran was added dropwise at room temperature. After heating to reflux for 30 minutes, 10 mL of a saturated aqueous solution of ammonium chloride was added dropwise and the solvent was concentrated under reduced pressure. Water was added to the residue and the mixture was extracted with ether, followed by washing with water and drying. The residue obtained by concentrating the solvent under reduced pressure was purified by chromatography on a silica gel column, whereby 12 g (yield: 87.0%) of 1-benzyl-4-(2-benzyloxyphenyl)-4-piperidinol was obtained.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ(ppm): 7.20-7.50(12H,m), 6.95-7.00(2H,m), 5.15(2H,s), 4.01(1H,s), 3.55(2H,s), 2.70-2.80(2H,m), 2.45-2.60(2H,m), 2.10-2.20(2H,m), 2.00-2.10(2H,m).

### Referential Example 3

[0039] In 100 mL of methanol was dissolved 12 g (32 mmol) of 1-benzyl-4-(2-benzyloxyphenyl)-4-piperidinol. To the resulting solution was added 3 g of 20% palladium hydroxide carbon and the resulting mixture was subjected to catalytic reduction at room temperature for 6 hours under 4 atmospheric pressure. After completion of the reaction, the catalyst was filtered off and the filtrate was concentrated under reduced pressure, whereby 6.7 g (yield: 100%) of 4-(2-hydrox-

yphenyl)-4-piperidinol was obtained.

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ(ppm): 7.22(1H,dd), 7.05(1H,ddd), 6.70-6.80(2H,m), 4.8(br.), 2.95(2H,ddd), 2.70-2.80(2H,m), 2.03(2H,ddd), 1.60-1.70(2H,m).

#### 5 Referential Example 4

[0040] In a similar manner to Referential Example 1 except for the use of diethylamine instead of a 50% aqueous solution of dimethylamine, diethyl(tetrahydro-3,3-diphenyl-2-furylidene)ammonium bromide was obtained (yield: 51.0%). <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ(ppm): 7.20-7.60(10H,m), 4.97(2H,t), 4.07(2H,q), 3.52(2H,t), 3.42(2H,q), 1.50(3H,t), 0.60(3H,t).

#### Referential Example 5

[0041] In a similar manner to Referential Example 1 except for the use of pyrrolidine instead of a 50% aqueous solution of dimethylamine, (tetrahydro-3,3-diphenyl-2-furylidene)pyrrolidinium bromide was obtained (yield: 53.6%). <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ(ppm): 7.25-7.70(10H,m), 4.88(2H,t), 4.37(2H,t), 3.50(2H,t), 2.88(2H,t), 1.80-2.30(4H,m).

#### Referential Example 6

[0042] In a mixed solvent of 60 mL of dioxane and 50 mL of water were dissolved 3.16 g (10 mmol) of 4-bromo-2,2-diphenylbutylnitrile and 1.93 g (10 mmol) of 4-(2-hydroxyphenyl)-4-piperidinol. To the resulting solution was added 2.76 g (20 mmol) of sodium carbonate, followed by heating under reflux for 12 hours. The reaction mixture was distilled under reduced pressure to remove the solvent. The residue thus obtained was dissolved in ethyl acetate, followed by washing with water and drying. The residue obtained by concentrating the solvent under reduced pressure was re-

crystallized from a mixed solvent of chloroform, ether and methanol, whereby 1.96 g (yield: 47.6%) of 4-(4-hydroxy-4-(2-hydroxyphenyl)piperidino)-2,2-diphenylbutylnitrile was obtained.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ(ppm): 9.69(1H,br), 7.20-7.50(11H,m), 7.00-7.15(1H,m), 6.70-6.80(2H,m), 5.47(1H,br), 2.55-2.75(4H,m), 2.20-2.40(4H,m), 2.10-2.20(2H,m), 1.62(2H,d).

#### 30 Referential Example 7

[0043] Reaction was conducted as in Referential Example 6, whereby 4-(4-hydroxy-4-((2-acetoxyethoxy)phenyl)piperidino)-2,2-diphenylbutylnitrile was obtained (yield: 99.0%).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ(ppm): 7.20-7.50(12H,m), 6.98(1H,t), 6.88(1H,d), 4.48(2H,t), 4.25(2H,t), 4.04(1H,s), 2.50-2.80(8H,m), 2.09(3H,s), 2.00-2.15(4H,m).

#### Referential Example 8

[0044] In 5 mL of chloroform was suspended 5.00 g (15.7 mmol) of 4-bromo-2,2-diphenylbutyric acid. Thionyl chloride (10 mL) was then added dropwise at room temperature. To the resulting mixture was added 0.1 mL of dimethylformamide, followed by heating under reflux for 5 hours. After completion of the reaction, the solvent was concentrated under reduced pressure, whereby 4-bromo-2,2-diphenylbutyric chloride was obtained. While stirring under ice cooling, 50 mL of cold methanol was added. The temperature was allowed to rise back to room temperature, and then stirring was conducted for 30 minutes. The residue obtained by concentrating the solvent under reduced pressure was purified by chromatography on a silica gel column, whereby 5.00 g (yield: 95.7%) of methyl 4-bromo-2,2-diphenylbutyrate was obtained.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ ppm: 7.10-7.50(10H,m), 3.71(3H,s), 2.80-3.30(4H,m).

#### Referential Example 9

[0045] In 50 mL of anhydrous dimethylformamide were dissolved 2.24 g (6.7 mmol) of methyl 4-bromo-2,2-diphenylbutyrate and 1.30 g (6.7 mmol) of 4-(2-hydroxyphenyl)-4-piperidinol. To the resulting solution was added 1.07 g (10 mmol) of sodium carbonate, followed by stirring under heating at 50°C for 35 hours. The residue obtained by distilling off the solvent under reduced pressure was dissolved in ethyl acetate, followed by washing with water and drying. The residue obtained by concentrating the solvent under reduced pressure was purified by chromatography on a silica gel column, whereby 870 mg (yield: 29.2%) of methyl 4-(4-hydroxy-4-(2-hydroxyphenyl)piperidino)-2,2-diphenylbutyrate was obtained.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ(ppm): 7.20-7.35(10H,m), 7.05-7.18(2H,m), 6.80-6.87(2H,m), 3.69(3H,s), 2.75-2.85(2H,m),

2.60-2.70(2H,m), 2.30-2.50(2H,m), 3.05-2.30(4H,m), 1.98(2H,d).

#### Referential Example 10

- 5 [0046] Reaction was conducted as in Referential Example 9, whereby methyl 4-(4-hydroxy-4-(2-(2-acetoxyethoxy)phenyl)piperidino)-2,2-diphenylbutyrate was obtained (yield: 77.3%).  
<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ(ppm): 6.80-7.40(14H,m), 4.36-4.60(2H,m), 4.10-4.35(2H,m), 4.05(1H,s), 3.69(3H,s), 1.80-2.90(12H,m), 2.09(3H,s).

#### 10 Referential Example 11

- [0047] In a mixture of 4 mL of a 25% aqueous solution of potassium hydroxide and 5 mL of ethylene glycol was dissolved 350 mg (0.66 mmol) of methyl 4-(4-hydroxy-4-(2-(2-acetoxyethoxy)phenyl)piperidino)-2,2-diphenylbutyrate. The resulting solution was stirred at 130°C for 2 hours. Water was added to the reaction mixture, followed by neutralization with hydrochloric acid under ice cooling. The crystals thus precipitated were collected by filtration and dried, whereby 230 mg (yield: 73.4%) of 4-(4-hydroxy-4-(2-(2-hydroxyethoxy)phenyl)piperidino)-2,2-diphenylbutyric acid was obtained.  
<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ(ppm): 7.36(1H,dd), 7.20-7.32(10H,m), 7.21(1H,dd), 6.95(1H,dt), 6.89(1H,dd), 4.10(2H,t), 4.00(2H,t), 3.69(3H,s), 3.51(2H,s), 2.00-2.90(10H,m), 1.90(2H,d).

20

#### Example 1

- [0048] In 20 mL of anhydrous dimethylformamide were dissolved 3.5 g (10 mmol) of dimethyl(tetrahydro-3,3-diphenyl-2-furylidene)ammonium bromide and 1.93 g (10 mmol) of 4-(2-hydroxyphenyl)-4-piperidinol. To the resulting solution was added 3.2 g (30 mmol) of sodium carbonate, followed by stirring at 80°C for 1.5 hours. The reaction mixture was distilled under reduced pressure to remove the solvent and the residue thus obtained was dissolved in ethyl acetate. The resulting solution was washed with water and dried. The residue obtained by concentrating the solvent under reduced pressure was purified by chromatography on a silica gel column, whereby 3.6 g (yield: 78.6%) of 4-(4-hydroxy-4-(2-hydroxyphenyl)piperidino)-N,N-dimethyl-2,2-diphenylbutaneamide (Compound No. 1) was obtained.

30

#### Example 2 (Reference)

- [0049] In a similar manner to Example 1 except for the use of 4-(3-hydroxyphenyl)-4-piperidinol instead of 4-(2-hydroxyphenyl)-4-piperidinol, whereby 4-(4-hydroxy-4-(3-hydroxyphenyl)piperidino)-N,N-dimethyl-2,2-diphenylbutaneamide (Reference Compound No. 2) (yield: 74.0%).

35

#### Example 3 (Reference)

- [0050] In a similar manner to Example 1 except for the use of 4-(4-hydroxyphenyl)-4-piperidinol instead of 4-(2-hydroxyphenyl)-4-piperidinol, whereby 4-(4-hydroxy-4-(4-hydroxyphenyl)piperidino)-N,N-dimethyl-2,2-diphenylbutaneamide (Compound No. 3) was obtained (yield: 55.0%).

40

#### Example 4

- [0051] In 20 mL of anhydrous dimethylformamide was dissolved 920 mg (2 mmol) of 4-(4-hydroxy-4-(2-hydroxyphenyl)piperidino)-N,N-dimethyl-2,2-diphenylbutaneamide. To the resulting solution were added 590 mg (3 mmol) of ethyl 4-bromo-n-butyrate, 414 mg (3 mmol) of potassium carbonate and a small amount of potassium iodide. The mixture was stirred under heating at 60°C for 2 hours. After cooling, the reaction mixture was poured into water, followed by extraction with ethyl acetate, washing with water and drying. The solvent was distilled off under reduced pressure. The residue thus obtained was purified by chromatography on a silica gel, whereby 500 mg (yield: 43.7%) of ethyl 4-(2-(1-(4-(dimethylamino)-4-oxo-3,3-diphenylbutyl)-4-hydroxy-4-piperidinyl)phenoxy)butyrate (Compound No. 4) was obtained.

50

#### Examples 5 to 24

55

- [0052] Reaction was effected as in Example 4, whereby Compounds Nos. 5 to 24 as described in the below lists were obtained.



## Example 25

[0053] In a liquid mixture of 5 mL of methanol and 5 mL of dioxane was dissolved 180 mg (0.32 mmol) of 4-(4-hydroxy-4-(2-(3-acetoxypoxy)phenyl)piperidino)-N,N-dimethyl-2,2-diphenylbutaneamide. To the resulting solution, 5 mL of a 1N aqueous solution of sodium hydroxide was added. The resulting mixture was stirred at room temperature for 1 hour. Water was added to the reaction mixture, followed by extraction with chloroform, washing with water and drying. The residue obtained by distilling off the solvent was purified by chromatography on a silica gel column, whereby 150 mg (yield: 89.8%) of 4-(4-hydroxy-4-(2-(3-hydroxypropoxy)phenyl)piperidino)-N,N-dimethyl-2,2-diphenylbutaneamide (Compound No. 25) was obtained.

## Examples 26 to 33

[0054] Reaction was effected as in Example 25, whereby Compounds Nos. 26 to 33 as described in the below list were obtained.

## Example 34.

[0055] In 10 mL of anhydrous dimethylformamide was dissolved 920 mg (2 mmol) of 4-(4-hydroxy-4-(2-hydroxyphenyl)piperidino)-N,N-dimethyl-2,2-diphenylbutaneamide. To the resulting solution were added 585 g (3 mmol) of 4-bromobutylacetate, 414 mg (3 mmol) of potassium carbonate and a small amount of potassium iodide. The resulting mixture was stirred under heating at 80°C for 4 hours. After cooling, the reaction mixture was poured into water, followed by extraction with ethyl acetate, washing with water and drying. The residue obtained by distilling off the solvent under reduced pressure was dissolved in 15 mL of methanol. To the resulting solution was added 3 mL of a 1N aqueous solution of sodium hydroxide, followed by stirring at room temperature for 1 hour. From the reaction mixture, the solvent was distilled off under reduced pressure. The residue thus obtained was dissolved in chloroform. The resulting solution was washed with water and dried. The residue obtained by distilling off the solvent under reduced pressure was purified by chromatography on a silica gel column, whereby 260 mg (yield: 24.5%) of 4-(4-hydroxy-4-(2-(4-hydroxybutoxy)phenyl)piperidino)-N,N-dimethyl-2,2-diphenylbutaneamide (Compound No. 34) was obtained.

## Examples 35 and 36

[0056] Reaction was effected as in Example 34, whereby Compounds Nos. 35 and 36 as described in the below list were obtained.

## Example 37

[0057] In 50 mL of anhydrous ether was dissolved 500 mg (0.9 mmol) of 4-(4-hydroxy-4-(2-(6-hydroxyhexyloxy)phenyl)piperidino)-N,N-dimethyl-2,2-diphenylbutaneamide (Compound No. 35). To the resulting solution was added 0.4 mL of a 4N solution of hydrochloric acid and dioxane under ice cooling and stirring. The white precipitate thus formed was collected by filtration, washed with ether and dried, whereby 460 mg (yield: 86.3%) of 4-(4-hydroxy-4-(2-(6-hydroxyhexyloxy)phenyl)piperidino)-N,N-dimethyl-2,2-diphenylbutaneamide hydrochloride (Compound No. 37) was obtained.

## Examples 38 to 63

[0058] Reaction was effected as in Example 37, whereby Compounds Nos. 38 to 63 as described in the below lists were obtained.

## Example 64

[0059] In a similar manner to Example 1 except for the use of diethyl(tetrahydro-3,3-diphenyl-2-furylidene)ammonium bromide instead of dimethyl(tetrahydro-3,3-diphenyl-2-furylidene)ammonium bromide, whereby 4-(4-hydroxy-4-(2-hydroxyphenyl)piperidino)-N,N-diethyl-2,2-diphenylbutaneamide (Compound No. 64) was obtained (yield: 66.0%).

## Example 65

[0060] In a similar manner to Example 1 except for the use of (tetrahydro-3,3-diphenyl-2-furylidene)pyrrolidinium bromide instead of dimethyl(tetrahydro-3,3-diphenyl-2-furylidene)ammonium bromide, whereby 4-(4-hydroxy-4-(2-hydroxyphenyl)piperidino)-N,N-diethyl-2,2-diphenylbutaneamide (Compound No. 65) was obtained (yield: 66.0%).

droxyphenyl)piperidino)-2,2-diphenyl-1-(1-pyrrolidinyl)-1-butanone (Compound No. 65) was obtained (yield: 99.0%).

#### Example 66

- 5 **[0061]** Reaction was effected as in Example 4, whereby Compound No. 66 as described in the below list was obtained.

#### Examples 67 and 68

- 10 **[0062]** Reaction was effected as in Example 25, whereby Compounds Nos. 67 and 68 as described in the below list were obtained.

#### Example 69

- 15 **[0063]** In 140 mL of anhydrous dimethylformamide was dissolved 20.8 g (43 mmol) of 4-(4-hydroxy-4-(2-hydroxyphenyl)piperidino)-2,2-diphenyl-1-(1-pyrrolidinyl)-1-butanone (Compound No. 65). To the resulting solution was added 3.85 g of potassium hydroxide (powder). The resulting mixture was stirred at room temperature for 0.5 hour. To the reaction mixture was added dropwise 7.9 g (47 mmol) of ethyl bromoacetate under ice cooling and stirring, followed by stirring at the same temperature for 10 minutes. After the reaction mixture was poured into water, extraction was effected with ethyl acetate. The extract was washed with water and then, dried. The solvent was distilled off under reduced pressure. 20 The residue thus obtained was purified by chromatography on a silica gel column, followed by crystallization from toluene, whereby 18.0 g (yield: 73.6%) of ethyl 2-(2-(1-(4-pyrrolidino-4-oxo-3,3-diphenylbutyl)-4-hydroxy-4-piperidinyl)) (phenoxy)acetate (Compound No. 69) was obtained. Example 70

- 25 **[0064]** In 15 mL of methanol was dissolved 780 mg (1.4 mmol) of ethyl 2-(2-(1-(4-(dimethylamino)-4-oxo-3,3-diphenylbutyl)-4-hydroxy-4-piperidinyl)) (phenoxy)acetate (Compound No. 53). To the resulting solution was added 5 mL of a 1N aqueous solution of sodium hydroxide. The resulting mixture was stirred at room temperature for 1 hour. After the reaction mixture was concentrated, water was added. The resulting mixture was then neutralized with 0.3 mL of acetic acid, followed by extraction with chloroform, washing with water and drying. The residue obtained by distilling off the solvent was crystallized from acetone, whereby 580 mg of 2-(2-(1-(4-(dimethylamino)-4-oxo-3,3-diphenylbutyl)-4-hydroxy-4-piperidinyl)) (phenoxy)acetic acid (Compound No. 70) was obtained (yield: 80.3%). 30

#### Example 71

- 35 **[0065]** In a similar manner to Example 70 except for the use of ethyl 2-(2-(1-(4-pyrrolidino-4-oxo-3,3-diphenylbutyl)-4-hydroxy-4-piperidinyl)) (phenoxy)acetate (Compound No. 69) instead of ethyl 2-(2-(1-(4-(dimethylamino)-4-oxo-3,3-diphenylbutyl)-4-hydroxy-4-piperidinyl)) (phenoxy)acetate, whereby 2-(2-(1-(4-pyrrolidino-4-oxo-3,3-diphenylbutyl)-4-hydroxy-4-piperidinyl)) (phenoxy)acetic acid (Compound No. 71) was obtained (yield: 81.0%).

#### Example 72

- 40 **[0066]** In a liquid mixture of 30 mL of a 40% aqueous solution of potassium hydroxide and 40 mL of ethylene glycol was dissolved 817 mg (1.64 mmol) of 4-(4-hydroxy-4-(2-(2-acetoxyethoxy)phenyl)piperidino)-2,2-diphenylbutylonitrile. The resulting solution was stirred at 170°C for 20 hours. After the addition of water, extraction was conducted with chloroform. The extract was washed with water and then dried. The residue obtained by distilling off the solvent under reduced pressure was purified by chromatography on a silica gel column, whereby 271 mg (yield: 34.9%) of 4-(4-hydroxy-4-(2-(2-hydroxyethoxy)phenyl)piperidino)-2,2-diphenylbutaneamide (Compound No. 72) was obtained. 45

#### Example 73


- 50 **[0067]** In 5 mL of anhydrous dimethylformamide was dissolved 81 mg (0.17 mmol) of 4-(4-hydroxy-4-(2-(2-acetoxyethoxy)phenyl)piperidino)-2,2-diphenylbutyric acid. The resulting solution was stirred at room temperature for 1 hour. To the reaction mixture were added 36 mg (0.22 mmol) of carbodiimidazole, and after one hour 16 mg (0.22 mmol) of n-butylamine. After stirring at 70°C for 24 hours, stirring was conducted for further 3 hours at 130°C, whereby the reaction was completed. Water was added to the reaction mixture, followed by extraction with ethyl acetate, washing with water and drying. The residue obtained by distilling off the solvent under reduced pressure was purified by chromatography on an alumina column and then chromatography on a silica gel column, whereby 35 mg (yield: 38.9%) of 4-(4-hydroxy-4-(2-(2-hydroxyethoxy)phenyl)piperidino)-N-butyl-2,2-diphenylbutaneamide (Compound No. 73) was obtained. 55

Examples 74 to 81

[0068] The reaction was conducted as in Example 37, whereby Compounds Nos. 74 to 81 were obtained.

Table 1

## Compound List



Comp'd No.	OR <sup>3</sup>	Yield (%)	Properties	Melting point (°C) (decomposed)
1	2-OH	78.6	Yellowish white amorphous substance	
2 *	3-OH	74.0	White crystals	169
3 *	4-OH	55.0	Yellowish white powder	155
4	2-O(CH <sub>2</sub> ) <sub>3</sub> COOEt	43.7	Yellow viscous liquid	
5	2-OCH <sub>2</sub> COOEt	49.0	White amorphous substance	
6	2-O(CH <sub>2</sub> ) <sub>5</sub> COOEt	58.3	Yellow viscous liquid	
7	2-OC(CH <sub>3</sub> ) <sub>2</sub> COOEt	27.4	Yellow viscous liquid	
8 *	3-OCH <sub>2</sub> COOEt	10.0	Yellow viscous liquid	
9 *	3-O(CH <sub>2</sub> ) <sub>3</sub> COOEt	47.0	Yellow viscous liquid	
10 *	3-O(CH <sub>2</sub> ) <sub>5</sub> COOEt	55.0	Yellow viscous liquid	
11 *	4-OCH <sub>2</sub> COOEt	17.0	White powder	
12 *	4-O(CH <sub>2</sub> ) <sub>3</sub> COOEt	35.0	Colorless viscous liquid	
13 *	4-O(CH <sub>2</sub> ) <sub>5</sub> COOEt	27.0	Colorless viscous liquid	
14	2-O(CH <sub>2</sub> ) <sub>2</sub> OAc	64.3	Colorless viscous liquid	
15	2-O(CH <sub>2</sub> ) <sub>3</sub> OAc	63.0	White amorphous substance	
16 *	3-O(CH <sub>2</sub> ) <sub>2</sub> OAc	55.0	Yellow viscous liquid	
17 *	3-O(CH <sub>2</sub> ) <sub>3</sub> OAc	44.0	Yellow viscous liquid	


\* Reference Compound

18 *	3-O(CH <sub>2</sub> ) <sub>4</sub> OAc	59.0	Yellow viscous liquid	
19 *	3-O(CH <sub>2</sub> ) <sub>6</sub> OAc	20.0	Yellow viscous liquid	
20 *	4-O(CH <sub>2</sub> ) <sub>3</sub> OAc	46.0	Colorless viscous liquid	

\* Reference Compound

Table 2

## Compound List




Comp'd No.	$\text{OR}^3$	Yield (%)	Properties	Melting point ( $^{\circ}\text{C}$ ) (decomposed)
21 *	4- $\text{O}(\text{CH}_2)_4\text{OAc}$	40.0	Colorless viscous liquid	
22 *	4- $\text{O}(\text{CH}_2)_6\text{OAc}$	38.0	Colorless viscous liquid	
23	2- $\text{OCH}_2\text{CONH}_2$	33.0	White amorphous substance	
24	2- $\text{O}(\text{CH}_2)_2\text{OMe}$	53.0	White amorphous substance	
25	2- $\text{O}(\text{CH}_2)_3\text{OH}$	89.8	White amorphous substance	
26	2- $\text{O}(\text{CH}_2)_2\text{OH}$	49.8	White amorphous substance	
27 *	3- $\text{O}(\text{CH}_2)_2\text{OH}$	74.0	White amorphous substance	
28 *	3- $\text{O}(\text{CH}_2)_3\text{OH}$	90.0	Colorless viscous liquid	
29 *	3- $\text{O}(\text{CH}_2)_4\text{OH}$	84.0	Colorless viscous liquid	
30 *	3- $\text{O}(\text{CH}_2)_6\text{OH}$	81.0	Colorless viscous liquid	
31 *	4- $\text{O}(\text{CH}_2)_3\text{OH}$	97.0	Colorless viscous liquid	
32 *	4- $\text{O}(\text{CH}_2)_4\text{OH}$	84.0	Colorless viscous liquid	
33 *	4- $\text{O}(\text{CH}_2)_6\text{OH}$	55.0	Colorless viscous liquid	
34	2- $\text{O}(\text{CH}_2)_4\text{OH}$	24.5	Colorless viscous liquid	
35	2- $\text{O}(\text{CH}_2)_6\text{OH}$	50.0	White amorphous substance	
36 *	4- $\text{O}(\text{CH}_2)_2\text{OH}$	11.0	Colorless viscous liquid	

\* Reference Compound

Table 3

## Compound List




Comp'd No.	OR <sup>3</sup>	Yield (%)	Properties	Melting point (°C) (decomposed)
37	2-O(CH <sub>2</sub> ) <sub>6</sub> OH	86.3	White powder	110
38	2-OH	52.9	Yellowish white powder	150
39	2-O(CH <sub>2</sub> ) <sub>2</sub> OAc	84.3	Yellowish white powder	105
40	2-O(CH <sub>2</sub> ) <sub>3</sub> OAc	56.3	White powder	120
41	2-O(CH <sub>2</sub> ) <sub>2</sub> OH	72.0	White powder	131
42	2-O(CH <sub>2</sub> ) <sub>3</sub> OH	77.8	White powder	140
43	2-O(CH <sub>2</sub> ) <sub>4</sub> OH	59.0	White powder	110
44	2-(OCH <sub>2</sub> ) <sub>2</sub> OMe	87.0	White powder	110
45 *	3-O(CH <sub>2</sub> ) <sub>2</sub> OH	72.0	White powder	113
46 *	3-O(CH <sub>2</sub> ) <sub>3</sub> OH	81.0	White powder	118
47 *	3-O(CH <sub>2</sub> ) <sub>4</sub> OH	83.0	White powder	128
48 *	3-O(CH <sub>2</sub> ) <sub>6</sub> OH	73.0	White powder	106
49 *	4-O(CH <sub>2</sub> ) <sub>2</sub> OH	48.8	Yellowish white powder	121
50 *	4-O(CH <sub>2</sub> ) <sub>3</sub> OH	52.0	Yellowish white powder	123
51 *	4-O(CH <sub>2</sub> ) <sub>4</sub> OH	52.7	Yellowish white powder	117
52 *	4-O(CH <sub>2</sub> ) <sub>6</sub> OH	61.0	Yellowish white powder	97
53	2-OCH <sub>2</sub> COOEt	71.4	White powder	118
54	2-O(CH <sub>2</sub> ) <sub>3</sub> COOEt	65.7	Yellowish white powder	105
55	2-O(CH <sub>2</sub> ) <sub>5</sub> COOEt	53.8	Yellowish white powder	80
56	2-OC(CH <sub>3</sub> ) <sub>2</sub> COOEt	70.4	Yellowish white powder	115

\* Reference Compound

Table 4

## Compound List




Comp'd No.	$\text{OR}^3$	Yield (%)	Properties	Melting point ( $^{\circ}\text{C}$ ) (decomposed)
57	2- $\text{OCH}_2\text{CO NH}_2$	93.3	White powder	120
58 *	3- $\text{OCH}_2\text{COOEt}$	68.0	White powder	118
59 *	3- $\text{O}(\text{CH}_2)_3\text{COOEt}$	78.0	Yellowish white powder	88
60 *	3- $\text{O}(\text{CH}_2)_5\text{COOEt}$	69.0	Yellowish white powder	86
61 *	4- $\text{OCH}_2\text{COOEt}$	64.0	White powder	105
62 *	4- $\text{O}(\text{CH}_2)_3\text{COOEt}$	61.1	Yellowish white powder	97
63 *	4- $\text{O}(\text{CH}_2)_5\text{COOEt}$	43.7	Yellowish white powder	73

\* Reference Compound

Table 5

## Compound List








Comp'd No.	NR <sub>1</sub> R <sub>2</sub>	OR <sub>3</sub>	Yield (%)	Properties	Melting point (°C) (decomposed)
64	NEt <sub>2</sub>	OH	66.0	Yellow oil	
65		OH	99.0	Yellowish white amorphous substance	
66	NEt <sub>2</sub>	OCH <sub>2</sub> COOEt	20.0	Yellowish white amorphous substance	
67	NEt <sub>2</sub>	OCH <sub>2</sub> CH <sub>2</sub> OH	43.2	Yellowish white amorphous substance	
68		OCH <sub>2</sub> CH <sub>2</sub> OH	47.5	White amorphous substance	
69		OCH <sub>2</sub> COOEt	73.6	White powder	129-131
70	NMe <sub>2</sub>	OCH <sub>2</sub> COOH	80.3	White powder	161-164
71		OCH <sub>2</sub> COOH	81.0	White powder	239-240
72	NH <sub>2</sub>	OCH <sub>2</sub> CH <sub>2</sub> OH	34.9	Yellow oil	
73	NH-n-Bu	OCH <sub>2</sub> CH <sub>2</sub> OH	38.9	White powder	130-131

Table 6

## Compound List






Comp'd No.	NR <sub>1</sub> R <sub>2</sub>	OR <sub>3</sub>	Yield (%)	Properties	Melting point (°C) (decomposed)
74	NEt <sub>2</sub>	OCH <sub>2</sub> COOEt	71.0	White powder	118
75	NEt <sub>2</sub>	OCH <sub>2</sub> CH <sub>2</sub> OH	45.0	White powder	130
76		OCH <sub>2</sub> CH <sub>2</sub> OH	62.0	White powder	145
77		OCH <sub>2</sub> COOEt	81.0	White powder	120
78	NMe <sub>2</sub>	OCH <sub>2</sub> COOH	97.4	White powder	175-176
79		OCH <sub>2</sub> COOH	87.2	White powder	155-160
80	NH <sub>2</sub>	OCH <sub>2</sub> CH <sub>2</sub> OH	52.0	White powder	144
81	NH-n-Bu	OCH <sub>2</sub> CH <sub>2</sub> OH	99.0	White powder	104



Table 7

Comp'd No.	Mass (FAB:(M+H) <sup>+</sup> )	<sup>1</sup> H-NMR δ:ppm (measured in CDCl <sub>3</sub> unless specifically indicated)
1	459	7.20-7.50(11H, m), 7.11(1H, ddd), 7.05(1H, dd), 6.75-6.82(2H, m), 2.90(1H, br. s), 2.89(3H, br. s), 2.65-2.75(2H, m), 2.20-2.50(7H, m), 2.00-2.20(4H, m), 1.93(2H, d)
2 *	459	in DMSO-d <sub>6</sub> : 9.11(1H, s), 7.25-7.50(10H, m), 7.05(1H, t), 6.85(1H, t), 6.80(1H, d), 6.56(1H, dd), 4.55(1H, br. s), 2.40-3.20(6H, br.), 2.50-2.60(2H, m), 2.20-2.50(4H, m), 2.00-2.20(2H, m), 1.70-1.90(2H, m), 1.48(2H, d)
3 *	459	in DMSO-d <sub>6</sub> : 9.21(1H, s), 7.30-7.50(10H, m), 7.20(2H, d), 6.71(2H, d), 5.00(1H, br. s), 2.00-3.60(16H, m), 1.66(2H, d)
4	573	7.15-7.50(12H, m), 6.85-6.95(2H, m), 4.14(2H, q), 4.08(2H, t), 3.99(1H, s), 2.98(3H, br. s), 2.60-2.70(2H, m), 2.48(2H, t), 2.20-2.60(7H, m), 1.80-2.20(8H, m), 1.25(3H, t)
5	545	7.25-7.50(11H, m), 7.18(1H, ddd), 6.95(1H, ddd), 6.75(1H, dd), 4.64(2H, s), 4.35(1H, s), 4.27(2H, q), 2.98(3H, br. s), 2.60-2.70(2H, m), 2.40-2.60(4H, m), 2.35(3H, br. s), 2.10-2.20(2H, m), 1.90-2.10(4H, m), 1.29(3H, t)
6	601	7.15-7.50(12H, m), 6.85-6.95(2H, m), 4.13(1H, s), 4.12(2H, q), 4.03(2H, t), 2.98(3H, br. s), 2.60-2.70(2H, m), 2.20-2.60(7H, m), 2.32(2H, t), 2.10-2.20(2H, m), 1.90-2.10(4H, m), 1.80-1.90(2H, quintet), 1.65-1.80(2H, quintet), 1.45-1.55(2H, m), 1.25(3H, t)
7	573	7.25-7.50(10H, m), 7.24(1H, dd), 7.13(1H, dt), 6.94(1H, t), 6.69(1H, d), 4.75(1H, br. s), 4.18(2H, q), 3.10-3.40(4H, br.), 3.00(3H, s), 2.50-2.90(6H, m), 2.31(3H, s), 2.18(2H, d), 1.70(6H, s), 1.15(3H, t)
8 *	545	7.20-7.50(11H, m), 7.00-7.10(2H, m), 6.76(1H, dd), 4.60(2H, s), 4.26(2H, q), 2.98(3H, br. s), 2.60-2.80(2H, m), 2.20-2.60(7H, m), 2.00-2.20(4H, m), 1.50-1.70(3H, m), 1.28(3H, t)
9 *	573	7.20-7.50(11H, m), 6.95-7.05(2H, m), 6.74(1H, dd), 4.13(2H, q), 3.98(2H, t), 2.98(3H, br. s), 2.60-2.80(2H, m), 2.20-2.60(7H, m), 2.49(2H, t), 2.00-2.20(6H, m), 1.63(2H, d), 1.56(1H, s), 1.25(3H, t)

\* Reference Compound

Table 8

Comp'd No.	Mass (FAB:(M+H) <sup>+</sup> )	<sup>1</sup> H-NMR δ:ppm (measured in CDCl <sub>3</sub> unless specifically indicated)
10 *	601	7.20-7.50(11H, m), 6.95-7.05(2H, m), 6.74(1H, dd), 4.12(2H, q), 3.93(2H, t), 2.98(3H, br. s), 2.60-2.80(2H, m), 2.20-2.60(7H, m), 2.32(2H, t), 2.00-2.20(4H, m), 1.60-1.80(6H, m), 1.40-1.60(2H, m), 1.25(3H, t)
11 *	545	7.20-7.50(12H, m), 6.80-6.85(2H, m), 4.58(2H, s), 4.25(2H, q), 2.95(3H, br. s), 2.65-2.85(2H, m), 2.00-2.60(8H, m), 2.32(3H, br. s), 1.65(2H, d), 1.28(3H, t)
12 *	573	7.20-7.50(12H, m), 6.82(2H, d), 4.13(2H, q), 3.98(2H, t), 2.98(3H, br. s), 2.65-2.75(2H, m), 2.45-2.55(2H, m), 2.49(2H, t), 2.20-2.50(5H, m), 1.95-2.20(6H, m), 1.64(2H, d), 1.48(1H, br. s), 1.24(3H, t)
13 *	601	7.20-7.50(12H, m), 6.82(2H, d), 4.12(2H, q), 3.93(2H, t), 2.98(3H, br. s), 2.65-2.75(2H, m), 2.55-2.65(2H, m), 2.20-2.60(5H, m), 2.32(2H, t), 2.10-2.20(2H, m), 2.03(2H, ddd), 1.78(2H, quintet), 1.60-1.75(4H, m), 1.45-1.55(3H, m), 1.25(3H, t)
14	545	7.15-7.50(12H, m), 6.94(1H, t), 6.85(1H, d), 4.45(2H, t), 4.22(2H, t), 3.95(1H, br. s), 2.99(3H, br. s), 1.90-2.80(13H, m), 2.08(3H, s), 1.70-1.90(2H, m)
15	559	7.15-7.50(12H, m), 6.93(1H, t), 6.89(1H, d), 4.24(2H, t), 4.13(2H, t), 4.05(1H, br. s), 2.98(3H, br. s), 1.90-2.80(13H, m), 2.15(2H, quintet), 2.06(3H, s), 1.60-1.90(2H, m)
16 *	545	7.00-7.50(13H, m), 6.80(1H, d), 4.10-4.50(4H, m), 3.10-3.40(4H, m), 2.95(3H, br. s), 2.28(3H, br. s), 2.08(3H, s), 2.40-3.10(6H, m), 1.80(2H, d)
17 *	559	7.00-7.50(13H, m), 6.75(1H, d), 4.24(2H, t), 4.03(2H, t), 2.95(3H, br. s), 2.00-3.00(15H, m), 2.04(3H, s), 1.80(2H, d)
18 *	573	7.00-7.50(13H, m), 6.80(1H, d), 3.90-4.20(4H, m), 2.00-3.20(16H, m), 2.03(3H, s), 1.60-2.00(6H, m)
19 *	601	7.00-7.60(13H, m), 6.80(1H, d), 3.80-4.20(4H, m), 2.60-3.50(10H, m), 2.98(3H, br. s), 2.29(3H, br. s), 2.03(3H, s), 1.20-2.20(10H, m)

\* Reference Compound

Table 9

Comp'd No.	Mass (FAB:(M+H) <sup>+</sup> )	<sup>1</sup> H-NMR δ:ppm (measured in CDCl <sub>3</sub> unless specifically indicated)
20 *	559	7.20-7.60(12H, m), 6.83(2H, d), 4.24(2H, t), 4.02(2H, t), 1.60-3.20(21H, m), 2.04(3H, s)
21 *	573	7.20-7.50(12H, m), 6.83(2H, d), 3.80-4.25(4H, m), 2.10-3.20(17H, m), 2.04(3H, s), 1.80-2.00(6H, m)
22 *	601	7.20-7.50(12H, m), 6.83(2H, d), 4.06(2H, t), 3.93(2H, t), 2.98(3H, br. s), 2.60-2.80(2H, m), 2.45-2.55(2H, m), 2.20-2.50(5H, m), 2.00-2.20(4H, m), 2.04(3H, s), 1.70-1.90(2H, m), 1.60-1.70(4H, m), 1.35-1.55(4H, m)
23	516	8.37(1H, br. s), 7.54(1H, dd), 7.20-7.50(11H, m), 7.01(1H, dd), 6.81(1H, d), 6.48(1H, br. s), 4.53(2H, s), 3.00(3H, br. s), 2.65-2.75(4H, m), 2.40-2.50(2H, m), 2.33(3H, br. s), 2.10-2.20(2H, m), 1.90-2.00(2H, m), 1.55(2H, d)
24	517	7.30-7.50(10H, m), 7.23(1H, dd), 7.18(1H, ddd), 6.91(1H, dd), 6.87(1H, d), 4.31(1H, s), 4.15(2H, dd), 3.71(2H, dd), 3.40(3H, s), 2.98(3H, br. s), 2.65-2.75(2H, m), 2.40-2.60(4H, m), 2.35(3H, br. s), 2.10-2.20(2H, m), 1.95-2.10(4H, m)
25	516	7.25-7.50(11H, m), 7.19(1H, ddd), 6.85-6.95(2H, m), 4.15(2H, t), 3.83(2H, t), 3.56(1H, s), 2.98(3H, br. s), 2.90(1H, br. s), 2.60-2.70(2H, m), 2.20-2.55(7H, m), 2.10-2.30(4H, m), 2.04(2H, quintet), 1.86(2H, d)
26	503	7.25-7.50(11H, m), 7.19(1H, ddd), 6.93(1H, ddd), 6.87(1H, d), 4.44(1H, br. s), 4.08(2H, t), 3.95(2H, br. t), 2.98(3H, br. s), 2.60-2.80(3H, m), 2.40-2.60(4H, m), 2.20-2.50(5H, m), 2.00-2.15(2H, m), 1.67(2H, d)
27 *	503	7.25-7.50(10H, m), 7.22(1H, dd), 7.07(1H, dd), 7.05(1H, d), 6.77(1H, dd), 4.08(2H, t), 3.93(2H, t), 2.98(3H, br. s), 2.65-2.75(2H, m), 2.40-2.55(2H, m), 2.20-2.50(5H, m), 2.10-2.20(2H, m), 2.06(2H, ddd), 1.63(2H, d)
28 *	517	7.20-7.50(10H, m), 7.21(1H, dd), 7.00-7.10(2H, m), 6.78(1H, dd), 4.11(2H, t), 3.84(2H, t), 2.98(3H, br. s), 2.60-2.80(2H, m), 2.40-2.50(2H, m), 2.20-2.50(5H, m), 2.02(2H, quintet), 2.00-2.20(7H, m), 1.62(2H, d), 1.60(1H, s)

\* Reference Compound

Table 10

Comp'd No.	Mass (FAB:(M+H) <sup>+</sup> )	<sup>1</sup> H-NMR δ:ppm (measured in CDCl <sub>3</sub> unless specifically indicated)
29 *	531	7.25-7.50(10H, m), 7.21(1H, dd), 7.00-7.10(2H, m), 6.75(1H, dd), 3.98(2H, t), 3.70(2H, t), 2.98(3H, br. s), 2.65-2.75(2H, m), 2.45-2.55(2H, m), 2.20-2.50(5H, m), 1.95-2.20(4H, m), 1.80-1.90(2H, m), 1.70-1.80(2H, m), 1.65(1H, s), 1.63(2H, d)
30 *	559	7.20-7.50(10H, m), 7.21(1H, dd), 7.00-7.10(2H, m), 6.75(1H, dd), 3.94(2H, t), 3.64(2H, t), 2.98(3H, br. s), 2.65-2.75(2H, m), 2.20-2.60(7H, m), 2.00-2.20(4H, m), 1.40-1.90(12H, m)
31 *	517	7.20-7.50(12H, m), 6.84(2H, d), 4.09(2H, t), 3.84(2H, t), 2.98(3H, br. s), 2.65-2.75(2H, m), 2.20-2.60(7H, m), 1.90-2.20(6H, m), 1.64(2H, d), 1.56(1H, br. s)
32 *	531	7.20-7.50(12H, m), 6.83(2H, d), 3.97(2H, t), 3.69(2H, t), 2.98(3H, br. s), 2.65-2.75(2H, m), 2.20-2.60(7H, m), 1.90-2.20(4H, m), 1.86(2H, quintet), 1.73(2H, quintet), 1.65(2H, d)
33 *	559	7.20-7.50(12H, m), 6.83(2H, d), 3.93(2H, t), 3.64(2H, t), 3.47(1H, s), 2.98(3H, br. s), 2.65-2.75(2H, m), 2.20-2.60(7H, m), 2.10-2.20(2H, m), 2.04(2H, ddd), 1.77(2H, quintet), 1.85(2H, d), 1.59(2H, quintet), 1.35-1.55(4H, m)
34	531	7.20-7.50(11H, m), 7.19(1H, ddd), 6.91(1H, dd), 6.87(1H, d), 4.05(2H, t), 3.70(2H, t), 3.50(1H, s), 2.98(3H, br. s), 2.65-2.75(2H, m), 2.10-2.60(11H, m), 1.80-2.00(2H, m), 1.81(2H, d), 1.70-1.80(2H, m)
35	559	7.15-7.50(12H, m), 6.85-6.95(2H, m), 4.10(1H, s), 4.03(2H, t), 3.66(2H, br. t), 2.97(3H, br. s), 2.65-2.75(2H, m), 2.40-2.60(6H, m), 2.34(3H, br. s), 1.90-2.20(6H, m), 1.82(2H, quintet), 1.61(2H, quintet), 1.40-1.60(4H, m)
36 *	503	7.20-7.50(12H, m), 6.85(2H, d), 4.05(2H, t), 3.93(2H, t), 2.98(3H, br. s), 2.65-2.75(2H, m), 2.45-2.55(2H, m), 2.20-2.40(5H, m), 2.10-2.20(2H, m), 2.04(2H, ddd), 1.64(2H, d), 1.55(1H, br. s)

\* Reference Compound

Table 11

Comp'd No.	Mass (FAB:(M+H) <sup>+</sup> )	<sup>1</sup> H-NMR δ:ppm (measured in CDCl <sub>3</sub> , unless specifically indicated)
37	559	in DMSO-d <sub>6</sub> : 10.7, 10.4 (total 1H, each br. s), 7.30-7.60 (11H, m), 7.19-7.24 (1H, m), 6.98 (1H, d), 6.91 (1H, dd), 5.32, 5.12 (total 1H, each s), 4.29 (1H, br. s), 3.95-4.10 (2H, m), 3.20-3.50 (4H, m), 2.80-3.20 (2H, m), 2.93 (3H, br. s), 2.67 (4H, s), 2.50-2.80 (2H, m), 2.25 (3H, br. s), 1.81 (2H, quintet), 1.71 (2H, d), 1.30-1.50 (8H, m)
38	459	in DMSO-d <sub>6</sub> : 10.6, 10.2 (total 1H, each br. s), 9.74, 9.55 (total 1H, each s), 7.20-7.60 (11H, m), 7.07 (1H, dd), 6.87, 6.83 (total 1H, each d), 6.77 (1H, dd), 5.61, 5.40 (total 1H, each br. s), 3.20-3.40 (2H, m), 2.90-3.20 (2H, m), 2.91 (3H, br. s), 2.67 (4H, s), 2.60-2.80 (2H, m), 2.25 (3H, br. s), 1.72, 1.40 (total 2H, each d)
39	545	in DMSO-d <sub>6</sub> : 10.6, 10.3 (total 1H, each br. s), 7.30-7.60 (11H, m), 7.24 (1H, dd), 7.01 (1H, d), 6.95 (1H, dd), 5.34, 5.10 (total 1H, each s), 4.45, 4.33 (total 2H, each t), 4.24, 4.20 (total 2H, each t), 3.20-3.60 (2H, m), 2.90-3.20 (2H, m), 2.94 (3H, br. s), 2.68 (4H, s), 2.55-2.75 (2H, m), 2.24 (3H, br. s), 2.00, 1.85 (total 3H, each s), 1.72, 1.41 (total 2H, each d)
40	559	in DMSO-d <sub>6</sub> : 10.2, 9.86 (total 1H, each br. s), 7.30-7.60 (11H, m), 7.23 (1H, ddd), 6.99 (1H, d), 6.93 (1H, dd), 5.32, 5.19 (total 1H, each s), 4.17, 4.13 (total 1H, each t), 4.08 (2H, t), 3.20-3.50 (2H, m), 3.00-3.20 (2H, m), 2.94 (3H, br. s), 2.67 (4H, s), 2.50-2.70 (2H, m), 2.25 (3H, br. s), 2.16 (2H, quintet), 2.02, 1.99 (total 3H, each s), 1.68, 1.42 (total 2H, each d)
41	503	in DMSO-d <sub>6</sub> : 10.5, 10.3 (total 1H, each br. s), 7.30-7.60 (11H, m), 7.18-7.26 (1H, m), 7.01, 6.96 (total 1H, each d), 6.92 (1H, dd), 5.33, 5.27 (total 1H, each s), 5.12, 4.76 (total 1H, each br. s), 4.03, 3.97 (total 2H, each t), 3.78, 3.65 (total 2H, each br. t), 3.20-3.50 (2H, m), 2.93 (3H, br. s), 2.60-3.20 (8H, m), 2.25 (3H, br. s), 1.61, 1.44 (total 2H, each d)

Table 12

Comp'd No.	Mass (FAB:(M+H) <sup>+</sup> )	<sup>1</sup> H-NMR δ:ppm (measured in CDCl <sub>3</sub> unless specifically indicated)
42	517	in DMSO-d <sub>6</sub> : 10.6, 10.3 (total 1H, each br. s), 7.30-7.60 (11H, m), 7.18-7.26 (1H, m), 6.87-7.02 (2H, m), 5.34, 5.24 (total 1H, each s), 4.60 (1H, br. s), 4.00-4.15 (2H, m), 3.55 (2H, t), 3.20-3.50 (2H, m), 2.94 (3H, br. s), 2.50-3.20 (8H, m), 2.25 (3H, br. s), 1.96, 1.84 (total 2H, each quintet), 1.69, 1.42 (total 2H, each d)
43	531	in DMSO-d <sub>6</sub> : 10.7, 10.4 (total 1H, each br. s), 7.30-7.60 (11H, m), 7.21 (1H, dd), 6.98 (1H, d), 6.90 (1H, dd), 5.30, 5.15 (total 1H, each br. s), 4.40 (1H, br. s), 4.00-4.10 (2H, m), 3.20-3.50 (4H, m), 2.90-3.20 (2H, m), 2.93 (3H, br. s), 2.68 (4H, s), 2.50-2.80 (2H, m), 2.25 (3H, br. s), 1.85, 1.71 (total 2H, each quintet), 1.70, 1.40 (total 2H, each d), 1.54 (2H, quintet)
44	517	in DMSO-d <sub>6</sub> : 10.5, 10.4 (total 1H, each br. s), 7.30-7.60 (11H, m), 7.23 (1H, ddd), 6.98-7.04 (1H, m), 6.90-6.96 (1H, m), 5.30, 5.10 (total 1H, each s), 4.17, 4.14 (total 2H, each t), 3.77, 3.58 (total 2H, each t), 3.31, 3.21 (total 3H, each s), 3.20-3.40 (2H, m), 2.90-3.20 (2H, m), 2.93 (3H, br. s), 2.55-2.75 (6H, m), 2.25 (3H, br. s), 1.75, 1.40 (total 2H, each d)
45 *	503	in DMSO-d <sub>6</sub> : 10.7 (1H, br. s), 7.30-7.50 (10H, m), 7.24 (1H, dd), 7.01 (1H, dd), 6.98 (1H, d), 6.81 (1H, dd), 5.33 (1H, s), 4.80 (1H, br. s), 3.97 (2H, t), 3.70 (2H, t), 3.20-3.40 (2H, m), 2.90-3.10 (2H, m), 2.92 (3H, br. s), 2.68 (4H, s), 2.38 (2H, ddd), 2.25 (3H, br. s), 1.69 (2H, d)
46 *	517	in DMSO-d <sub>6</sub> : 10.7 (1H, br. s), 7.30-7.50 (10H, m), 7.23 (1H, dd), 7.00 (1H, dd), 6.97 (1H, d), 6.80 (1H, dd), 5.33 (1H, s), 4.49 (1H, br. s), 4.02 (2H, t), 3.55 (2H, t), 3.20-3.40 (2H, m), 2.90-3.10 (2H, m), 2.92 (3H, br. s), 2.68 (4H, s), 2.38 (2H, ddd), 2.25 (3H, br. s), 1.85 (2H, quintet), 1.69 (2H, d)
47 *	531	in DMSO-d <sub>6</sub> : 10.6 (1H, br. s), 7.30-7.50 (10H, m), 7.23 (1H, dd), 6.98-7.02 (1H, m), 6.98 (1H, d), 6.79 (1H, dd), 5.32 (1H, s), 4.37 (1H, br. s), 3.95 (2H, t), 3.44 (2H, t), 3.20-3.40 (2H, m), 2.90-3.10 (2H, m), 2.93 (3H, br. s), 2.68 (4H, s), 2.38 (2H, ddd), 2.25 (3H, br. s), 1.60-1.80 (4H, m), 1.55 (2H, quintet)

\* Reference Compound



Table 13

Comp'd No.	Mass (FAB:(M+H) <sup>+</sup> )	<sup>1</sup> H-NMR δ:ppm (measured in CDCl <sub>3</sub> unless specifically indicated)
48 *	559	in DMSO-d <sub>6</sub> : 10.6(1H, br. s), 7.30-7.50(10H, m), 7.24(1H, dd), 6.98-7.02(1H, m), 6.96(1H, d), 6.79(1H, dd), 5.32(1H, s), 4.28(1H, br. s), 3.94(2H, t), 3.39(2H, t), 3.20-3.40(2H, m), 2.90-3.10(2H, m), 2.93(3H, br. s), 2.68(4H, s), 2.37(2H, ddd), 2.25(3H, br. s), 1.60-1.75(4H, m), 1.30-1.50(6H, m)
49 *	503	in DMSO-d <sub>6</sub> : 10.6(1H, br. s), 7.25-7.50(12H, m), 6.89(2H, d), 5.22(1H, s), 4.77(1H, br. s), 3.96(2H, t), 3.69(2H, br. t), 3.20-3.40(2H, m), 2.90-3.20(2H, m), 2.92(3H, br. s), 2.67(4H, s), 2.00-2.50(5H, m), 1.69(2H, d)
50 *	517	in DMSO-d <sub>6</sub> : 10.8(1H, br. s), 7.25-7.50(12H, m), 6.88(2H, d), 5.22(1H, s), 4.46(1H, br. s), 4.01(2H, t), 3.54(2H, t), 3.20-3.40(2H, m), 2.90-3.20(2H, m), 2.92(3H, br. s), 2.67(4H, s), 2.10-2.50(5H, m), 1.83(2H, quintet), 1.69(2H, d)
51 *	531	in DMSO-d <sub>6</sub> : 10.7(1H, br. s), 7.25-7.50(12H, m), 6.87(2H, d), 5.22(1H, br. s), 4.35(1H, br. s), 3.95(2H, t), 3.44(2H, t), 3.20-3.40(2H, m), 2.90-3.20(2H, m), 2.93(3H, br. s), 2.68(4H, s), 2.00-2.50(5H, m), 1.65-1.80(4H, m), 1.50-1.60(2H, m)
52 *	559	in DMSO-d <sub>6</sub> : 10.5(1H, br. s), 7.25-7.50(12H, m), 6.87(2H, d), 5.21(1H, s), 4.28(1H, br. s), 3.93(2H, t), 3.38(2H, br. t), 3.20-3.40(2H, m), 2.90-3.20(2H, m), 2.93(3H, br. s), 2.67(4H, s), 2.10-2.40(5H, m), 1.60-1.80(4H, m), 1.30-1.50(6H, m)
53	545	in DMSO-d <sub>6</sub> : 10.6, 10.5(total 1H, each br. s), 7.30-7.60(11H, m), 7.16-7.24(1H, m), 6.97, 6.95(total 1H, each dd), 6.88, 6.83(total 1H, each d), 5.38, 5.22(total 1H, each br. s), 4.89, 4.85(total 2H, each s), 4.20, 4.14(total 2H, each q), 3.20-3.50(2H, m), 2.92(3H, br. s), 2.60-3.20(8H, m), 2.24(3H, br. s), 1.65, 1.40(total 2H, each d), 1.23, 1.18(total 3H, each t),

\* Reference Compound



Table 14

Comp'd No.	Mass (FAB:(M+H) <sup>+</sup> )	<sup>1</sup> H-NMR δ:ppm (measured in CDCl <sub>3</sub> , unless specifically indicated)
54	573	in DMSO-d <sub>6</sub> : 10.7, 10.4 (total 1H, each br. s), 7.30-7.60 (11H, m), 7.18-7.26 (1H, m), 6.95-7.02 (1H, m), 6.92 (1H, dd), 5.33, 5.16 (total 1H, each br. s), 4.00-4.20 (4H, m), 3.20-3.40 (2H, m), 2.95-3.15 (2H, m), 2.93 (3H, br. s), 2.68 (4H, s), 2.50-2.75 (2H, m), 2.40-2.50 (2H, m), 2.25 (3H, br. s), 2.07, 1.95 (total 2H, each quintet), 1.70, 1.43 (total 2H, each d), 1.20, 1.17 (total 3H, each t)
55	601	in DMSO-d <sub>6</sub> : 10.8, 10.5 (total 1H, each br. s), 7.30-7.60 (11H, m), 7.18-7.24 (1H, m), 6.98 (1H, d), 6.88-6.95 (1H, m), 5.30, 5.10 (total 1H, each br. s), 3.95-4.10 (4H, m), 3.20-3.50 (2H, m), 2.90-3.20 (2H, m), 2.93 (3H, br. s), 2.50-2.80 (6H, m), 2.20-2.40 (2H, m), 2.24 (3H, br. s), 1.30-1.90 (8H, m), 1.18, 1.16 (total 3H, each t)
56	573	in DMSO-d <sub>6</sub> : 9.80, 9.35 (total 1H, each br. s), 7.30-7.70 (11H, m), 7.10-7.20 (1H, m), 6.94 (1H, dd), 6.54, 6.50 (total 1H, each dd), 5.35, 5.22 (total 1H, each br. s), 4.15 (2H, q), 3.20-3.50 (2H, m), 3.00-3.20 (2H, m), 2.94 (3H, br. s), 2.60-2.75 (6H, m), 2.25 (3H, br. s), 1.72 (2H, d), 1.66, 1.49 (total 6H, each s), 1.12 (3H, t)
57	516	in DMSO-d <sub>6</sub> : 10.42, 10.39 (total 1H, each br. s), 7.57 (1H, br. s), 7.30-7.50 (11H, m), 7.30 (1H, br. s), 7.24 (1H, ddd), 6.90-7.00 (1H, m), 6.89, 6.84 (total 1H, each d), 5.49, 5.46 (total 1H, each s), 4.55, 4.51 (total 2H, each s), 3.20-3.40 (2H, m), 2.70-3.20 (5H, m), 2.68 (4H, s), 2.61 (2H, ddd), 2.25 (3H, br. s), 1.87, 1.54 (total 2H, each d)
58 *	545	in DMSO-d <sub>6</sub> : 10.7 (1H, br. s), 7.30-7.50 (10H, m), 7.25 (1H, dd), 6.95-7.05 (2H, m), 6.78 (1H, dd), 5.35 (1H, s), 4.73 (2H, s), 4.16 (2H, q), 3.20-3.40 (2H, m), 2.90-3.10 (2H, m), 2.92 (3H, br. s), 2.68 (4H, s), 2.37 (2H, ddd), 2.25 (3H, br. s), 1.69 (2H, d), 1.20 (3H, t)

\* Reference Compound

Table 15

Comp'd No.	Mass (FAB:(M+H) <sup>+</sup> )	<sup>1</sup> H-NMR δ:ppm (measured in CDCl <sub>3</sub> unless specifically indicated)
59 *	573	in DMSO-d <sub>6</sub> : 10.8(1H, br. s), 7.30-7.50(10H, m), 7.23(1H, dd), 6.90-7.10(2H, m), 6.79(1H, d), 5.33(1H, s), 4.06(2H, q), 3.97(2H, t), 3.20-3.40(2H, m), 2.90-3.20(2H, m), 2.92(3H, br. s), 2.68(4H, s), 2.44(2H, t), 2.30-2.50(2H, m), 2.25(3H, br. s), 1.96(2H, quintet), 1.68(2H, d), 1.17(3H, t)
60 *	601	in DMSO-d <sub>6</sub> : 10.8(1H, br. s), 7.30-7.50(10H, m), 7.23(1H, dd), 6.95-7.05(2H, m), 6.78(1H, dd), 5.32(1H, s), 4.04(2H, q), 3.93(2H, t), 3.20-3.40(2H, m), 2.90-3.10(2H, m), 2.92(3H, br. s), 2.68(4H, s), 2.39(2H, ddd), 2.29(2H, t), 2.00-2.40(3H, m), 1.60-1.80(4H, m), 1.58(2H, quintet), 1.40-1.50(2H, m), 1.17(3H, t)
61 *	545	in DMSO-d <sub>6</sub> : 10.5(1H, br. s), 7.30-7.50(12H, m), 6.88(2H, d), 5.25(1H, s), 4.73(2H, s), 4.16(2H, q), 3.20-3.40(2H, m), 2.90-3.10(2H, m), 2.93(3H, br. s), 2.67(4H, s), 2.00-2.50(5H, m), 1.69(2H, d), 1.21(3H, t)
62 *	573	in DMSO-d <sub>6</sub> : 10.7(1H, br. s), 7.25-7.50(12H, m), 6.87(2H, d), 5.23(1H, br. s), 4.06(2H, q), 3.96(2H, t), 3.20-3.40(2H, m), 2.90-3.20(2H, m), 2.93(3H, br. s), 2.68(4H, s), 2.43(2H, t), 2.10-2.50(5H, m), 1.95(2H, quintet), 1.69(2H, d), 1.17(3H, t)
63 *	601	in DMSO-d <sub>6</sub> : 10.8(1H, br. s), 7.25-7.50(12H, m), 6.87(2H, d), 5.22(1H, s), 4.04(2H, q), 3.92(2H, t), 3.20-3.40(2H, m), 2.90-3.20(2H, m), 2.93(3H, br. s), 2.68(4H, s), 2.10-2.50(5H, m), 2.29(2H, t), 1.60-1.80(4H, m), 1.58(2H, quintet), 1.35-1.50(2H, m), 1.17(3H, t)

\* Reference Compound

Table 16

Comp'd No.	Mass (FAB:(M+H) <sup>+</sup> )	<sup>1</sup> H-NMR δ:ppm (measured in CDCl <sub>3</sub> unless specifically indicated)
6 4	487	7.20-7.50 (10H, m) 7.10 (1H, ddd) 7.04 (1H, dd) 6.75-6.85 (2H, m) 3.30 (2H, q) 2.82 (2H, q) 2.65-2.75 (2H, m) 2.35-2.55 (4H, m) 2.00-2.20 (4H, m) 1.92 (2H, d) 1.13 (3H, t) -0.01 (3H, t)
6 5	485	7.20-7.40 (10H, m) 7.05-7.15 (2H, m) 6.75-6.85 (2H, m) 3.36 (2H, t) 2.70-2.90 (2H, m) 2.40-2.60 (4H, m) 2.40 (2H, t) 2.00-2.30 (4H, m) 1.98 (2H, d) 1.56 (2H, quintet) 1.46 (2H, quintet)
6 6	573	7.15-7.50 (12H, m) 6.96 (1H, dd) 6.75 (1H, d) 4.65 (2H, s) 4.50 (1H, br) 4.27 (2H, q) 3.36 (2H, q) 2.84 (2H, q) 1.80-3.00 (12H, m) 1.30 (3H, t) 1.19 (3H, t) 0.01 (3H, t)
6 7	531	7.15-7.50 (12H, m) 6.93 (1H, dd) 6.87 (1H, d) 5.00 (1H, br) 4.00-4.10 (2H, m) 3.90-4.00 (2H, m) 3.36 (2H, q) 2.55-3.00 (7H, m) 2.40-2.55 (2H, m) 2.25-2.35 (2H, m) 1.95-2.05 (2H, m) 1.59 (2H, d) 1.18 (3H, t) 0.00 (3H, t)
6 8	529	7.47 (1H, dd) 7.25-7.40 (10H, m) 7.20 (1H, ddd) 6.93 (1H, ddd) 6.87 (1H, dd) 4.80 (1H, br) 4.06 (2H, t) 3.97 (2H, t) 3.58 (2H, t) 2.40-2.80 (9H, m) 2.30-2.40 (2H, m) 2.05-2.15 (2H, m) 1.67 (2H, quintet) 1.62 (2H, d) 1.52 (2H, quintet)
6 9	571	7.20-7.50 (11H, m) 7.19 (1H, ddd) 6.96 (1H, dd) 6.75 (1H, d) 4.65 (2H, s) 4.38 (1H, s) 4.27 (2H, q) 3.59 (2H, t) 2.60-2.80 (2H, m) 2.40-2.60 (6H, m) 1.95-2.40 (6H, m) 1.67 (2H, quintet) 1.52 (2H, quintet) 1.29 (3H, t)
7 0	517	in DMSO-d <sub>6</sub> : 7.30-7.50 (11H, m) 7.10 (1H, ddd) 6.86 (1H, dd) 6.77 (1H, d) 4.33 (2H, s) 2.00-3.10 (16H, m) 1.56 (2H, d)
7 1	543	in DMSO-d <sub>6</sub> : 7.30-7.50 (11H, m) 7.09 (1H, dd) 6.86 (1H, dd) 6.77 (1H, d) 4.34 (2H, s) 3.40-3.60 (2H, m) 3.00-3.20 (2H, m) 2.75-2.95 (2H, m) 2.50-2.70 (6H, m) 2.30-2.50 (2H, m) 1.40-1.70 (6H, m)
7 2	475	7.39 (1H, dd) 7.20-7.35 (10H, m) 7.20 (1H, dd) 6.93 (1H, t) 6.86 (1H, d) 6.03 (1H, br) 4.05 (2H, t) 3.92 (2H, t) 3.70 (1H, br) 2.80-2.95 (2H, m) 2.73 (2H, t) 2.63 (2H, t) 2.40-2.57 (4H, m) 1.82 (2H, d)

Table 17

7 3	531	6.97(1H, t) 6.88(1H, d) 7.10-7.40(12H, m) 4.86(1H, br) 4.45(2H, t) 4.25(1H, s) 4.21(2H, t) 3.98(1H, t) 3.15(2H, q) 2.70-2.85(2H, m) 2.50-2.65(2H, m) 2.30-2.50(4H, m) 2.00-2.20(4H, m) 1.45(2H, q) 1.31(2H, q) 0.89(3H, t)
7 4	573	in DMSO-d6: 10.5, 10.4(total 1H, each br. s) 7.30-7.60(11H, m) 7.15-7.25(1H, m) 6.90-7.00(1H, m) 6.87, 6.83(total 1H, each d) 5.35, 5.21(total 1H, each br. s) 4.88, 4.78(total 2H, each s) 4.20, 4.14(total 2H, each q) 3.10-3.40(4H, m) 2.50-3.10(10H, m) 1.65, 1.39(total 2H, each d) 1.23, 1.18(total 3H, each t) 1.13(3H, br. t) -0.04(3H, br. t)
7 5	531	in DMSO-d6: 10.4, 10.2(total 1H, each br. s) 7.30-7.60(11H, m) 7.18-7.26(1H, m) 6.88-7.02(2H, m) 4.80-5.40(2H, br.) 4.03, 3.97(total 2H, each t) 3.78, 3.64(total 2H, each t) 2.95- 3.45(6H, m) 2.55-2.90(8H, m) 1.61, 1.43(total 2H, each d) 1.05- 1.24(3H, br. t) -0.25 ~ 0.10(3H, br. t)
7 6	529	in DMSO-d6: 10.4, 10.2(total 1H, each br. s) 7.30-7.60(11H, m) 7.22(1H, ddd) 6.97(1H, d) 6.93(1H, dd) 5.31, 5.27(total 1H, each s) 5.10, 4.75(total 1H, each br. s) 4.02, 3.98(total 2H, each t) 3.75-3.85, 3.60-3.70(total 2H, each m) 3.40-3.55(2H, m) 3.20- 3.35(2H, m) 3.00-3.15(2H, m) 2.55-3.00(6H, m) 2.30-2.40(2H, m) 1.40-1.70(6H, m)
7 7	571	in DMSO-d6: 10.5, 10.4(total 1H, each br. s) 7.20-7.60(12H, m) 6.92-7.00(1H, m) 6.88, 6.84(total 1H, each dd) 5.36, 5.23(total 1H, each br. s) 4.89, 4.85(total 2H, each s) 4.19, 4.15(total 2H, each q) 3.15-3.55(4H, m) 2.95-3.15(2H, m) 2.60-2.90(6H, m) 2.25-2.45(2H, m) 1.35-1.75(6H, m) 1.22, 1.19(total 3H, each t)
7 8	517	in DMSO-d6: 13.0(1H, br.) 10.6, 10.4(total 1H, each br. s) 7.30- 7.60(11H, m) 7.20(1H, ddd) 6.94(1H, dd) 6.83(1H, d) 5.30(1H, br.) 4.79, 4.74(total 2H, each s) 2.50-3.50(13H, m) 2.25(3H, br. s) 1.67, 1.41(total 2H, each d)
7 9	543	10.8(1H, br. s) 7.10-7.50(12H, m) 6.95(1H, dd) 6.78(1H, d) 5.50(2H, br) 4.61(2H, s) 3.56(2H, t) 3.30-3.40(2H, m) 3.15- 3.30(2H, m) 2.75-2.90(4H, m) 2.55-2.75(2H, m) 2.40(2H, t) 2.20(2H, d) 1.71(2H, quintet) 1.55(2H, quintet)

Table 18

8 0	475	11.27 (1H, br) 7.45 (1H, dd) 6.92 (1H, t) 6.87 (1H, d) 6.01 (1H, s) 5.80 (1H, s) 4.00-4.06 (4H, m) 3.79 (1H, br) 3.30-3.40 (2H, m) 3.10-3.30 (2H, m) 2.90-3.10 (6H, m) 1.75-1.90 (2H, m)
8 1	531	12.11 (1H, br) 7.20-7.35 (12H, m) 6.97 (1H, t) 6.86 (1H, d) 4.85 (1H, br) 4.57 (1H, s) 4.40-4.50 (2H, m) 4.15-4.25 (2H, m) 3.97 (1H, t) 3.25-3.45 (4H, m) 3.10-3.20 (2H, m) 2.85-2.95 (2H, m) 2.65- 2.80 (4H, m) 2.15-2.27 (2H, m) 1.37-1.50 (2H, m) 1.20-1.37 (2H, m) 0.89 (3H, t)

Test 1: Action on the ileum sample excised from a guinea pig

[0069] A Hartley male guinea pig of about 500 g in weight was employed. From its ileocecum, 15 to 30 cm of the ileum was excised and a longitudinal muscle sample attached with the Auerbach's plexus was prepared. Using the resulting sample, opioid receptor activity of a test drug was measured in accordance with the method proposed by Oka, et al (Eur. J. Pharmacol., 77; 137-141, 1982). The agonist activity was indicated in terms of relative potency to DAMGO ([D-Ala<sup>2</sup>, N-MePhe<sup>4</sup>, Gly<sup>5</sup>-ol]-enkephalin), a selective  $\mu$ -opioid agonist. The test drug was confirmed to be an opioid agonist by antagonism by naloxone.

[0070] Results are shown in Table 19.

Table 19

Compound No.	Relative potency
39	10
41	8.4
42	8.0
43	5.0
53	8.3
57	6.0
77	8.2
78	26
DAMGO	1.0
Morphine	0.14
Loperamide	4.3

Test 2: Action against righting reflex of a 10-day-old rat

[0071] It has been revealed (Oka, et al., Dev. Brain Res. 69; 271-276, 1992) that the righting reflex of a 10-day-old rat is suppressed by a  $\mu$ -opioid receptor agonist and this suppression is antagonized by naloxone. The test drug was therefore administered subcutaneously to a 10-day-old rat to study the administration amount required for disappearance of righting reflex.

[0072] Results are shown in Table 20.

Table 20


Comp' d No.	Administration amount required for disappearance of righting reflex ( $\mu\text{mol/kg}$ )
38	1
42	1
53	0.3
morphine	3

### Capability of Exploitation in Industry

[0073] The 4-hydroxy-4-phenylpiperidine derivative or salt thereof (1) according to the present invention exhibits excellent  $\mu$ -opioid agonist action and is therefore useful as a peripheral analgesic.

### Claims

1. A 4-hydroxy-4-phenylpiperidine derivative represented by the following formula (1):



[wherein,

R<sup>1</sup> and R<sup>2</sup> are the same or different and each independently represents

a hydrogen atom,  
a C<sub>1-6</sub> alkyl group or  
a cycloalkyl group, or

R<sup>1</sup> and R<sup>2</sup> may form

a pyrrolidinyl ring together with the adjacent nitrogen atom,

R<sup>3</sup> represents

a hydrogen atom or  
a group (CR<sup>4</sup>R<sup>5</sup>)<sub>n</sub>-Y  
(in which,

R<sup>4</sup> and R<sup>5</sup> each represents

a hydrogen atom or  
a C<sub>1-6</sub> alkyl group,

Y represents a group

-COOR<sup>6</sup>, -CONR<sup>7</sup>R<sup>8</sup>, -OR<sup>9</sup> or -OCOR<sup>10</sup>.

(in which  
 $R^6$ ,  $R^9$  and  $R^{10}$  each independently represents

a hydrogen atom,  
 a  $C_{1-6}$  alkyl group or  
 a cycloalkyl group,

$R^7$  and  $R^8$  are the same or different and each  
 independently represents

a hydrogen atom,  
 a  $C_{1-6}$  alkyl group or  
 a cycloalkyl group or

$R^7$  and  $R^8$  may form a heterocyclic ring together with the adjacent nitrogen atom), and


$n$  stands for 1 to 6)),

or salt thereof.

2. A compound according to claim 1, wherein  $R^1$  and  $R^2$  are the same or different and each independently represents a hydrogen atom, a  $C_{1-6}$  alkyl group or a  $C_{3-8}$  cycloalkyl group, or  $R^1$  and  $R^2$  may form, together with the adjacent nitrogen atom, a pyrrolidinyll heterocyclic ring,  $R^3$  represents a hydrogen atom or a group  $-(CR^4R^5)_n-Y$  (in which,  $R^4$  and  $R^5$  each represents a hydrogen atom or a  $C_{1-6}$  alkyl group,  $Y$  represents a group  $-COOR^6$ ,  $-CONR^7R^8$ ,  $-OR^9$  or  $-OCOR^{10}$  (in which  $R^6$ ,  $R^9$  and  $R^{10}$  each independently represents a hydrogen atom, a  $C_{1-6}$  alkyl group or a  $C_{3-8}$  cycloalkyl group,  $R^7$  and  $R^8$  are the same or different and each independently represents a hydrogen atom, a  $C_{1-6}$  alkyl group or a  $C_{3-8}$  cycloalkyl group or  $R^7$  and  $R^8$  may form, together with the adjacent nitrogen atom, a 3 to 8-membered heterocyclic ring).
3. A medicament comprising a 4-hydroxy-4-phenylpiperidine derivative or salt thereof as claimed in claim 1 or 2 as an effective ingredient.
4. A medicament according to claim 3, which is a peripheral analgesic.
5. A pharmaceutical composition comprising a 4-hydroxy-4-phenylpiperidine derivative or salt thereof as claimed in claim 1 or 2 and a pharmaceutically acceptable carrier.
6. Use of a 4-hydroxy-4-phenylpiperidine derivative or salt thereof as claimed in claim 1 or 2 for the preparation of a medicament for the treatment of pain.
7. Use according to claim 6, wherein said medicament is a peripheral analgesic.

#### Patentansprüche

1. 4-Hydroxy-4-phenylpiperidin-Derivat der folgenden Formel (1) oder ein Salz desselben:



[worin,

R<sup>1</sup> und R<sup>2</sup> gleich oder verschieden sind und unabhängig voneinander für

ein Wasserstoffatom,  
eine C<sub>1-6</sub> Alkylgruppe oder  
eine Cycloalkylgruppe stehen oder

R<sup>1</sup> und R<sup>2</sup> zusammen mit dem benachbarten Stickstoffatom einen Pyrrolidinyrning bilden,  
R<sup>3</sup> für

ein Wasserstoffatom oder  
-(CR<sup>4</sup>R<sup>5</sup>)<sub>n</sub>-Y steht  
(wobei,

R<sup>4</sup> und R<sup>5</sup> jeweils

ein Wasserstoffatom oder  
eine C<sub>1-6</sub> Alkylgruppe ist,

Y

-COOR<sup>6</sup>, -CONR<sup>7</sup>R<sup>8</sup>, -OR<sup>9</sup> oder -OCOR<sup>10</sup> ist  
(wobei  
R<sup>6</sup>, R<sup>9</sup> und R<sup>10</sup> unabhängig voneinander

ein Wasserstoffatom,  
eine C<sub>1-6</sub> Alkylgruppe oder  
eine Cycloalkylgruppe ist, und

R<sup>7</sup> und R<sup>8</sup> gleich oder verschieden sind und unabhängig voneinander für

ein Wasserstoffatom,  
eine C<sub>1-6</sub> Alkylgruppe oder  
eine Cycloalkylgruppe stehen oder

R<sup>7</sup> und R<sup>8</sup> zusammen mit dem benachbarten Stickstoffatom einen heterocyclischen Ring bilden),  
und

n ist eine Zahl von 1 bis 6 ist)].


2. Eine Verbindung gemäß Anspruch 1, worin R<sup>1</sup> und R<sup>2</sup> gleich oder verschieden sind und unabhängig voneinander für ein Wasserstoffatom, eine C<sub>1-6</sub> Alkylgruppe oder eine C<sub>3-8</sub> Cycloalkylgruppe stehen, oder R<sup>1</sup> und R<sup>2</sup> zusammen mit dem benachbarten Stickstoffatom einen heterocyclischen Pyrrolidinyrning bilden, R<sup>3</sup> ein Wasserstoffatom oder -(CR<sup>4</sup>R<sup>5</sup>)<sub>n</sub>-Y ist (worin R<sup>4</sup> und R<sup>5</sup> jeweils ein Wasserstoffatom oder eine C<sub>1-6</sub> Alkylgruppe und Y -COOR<sup>6</sup>, -CONR<sup>7</sup>R<sup>8</sup>, -OR<sup>9</sup> oder -OCOR<sup>10</sup> ist (wobei R<sup>6</sup>, R<sup>9</sup> und R<sup>10</sup> jeweils unabhängig voneinander für ein Wasserstoffatom, eine C<sub>1-6</sub> Alkylgruppe oder eine C<sub>3-8</sub> Cycloalkylgruppe stehen, R<sup>7</sup> und R<sup>8</sup> gleich oder verschieden sind und unabhängig voneinander ein Wasserstoffatom, eine C<sub>1-6</sub> Alkylgruppe oder eine C<sub>3-8</sub> Cycloalkylgruppe sind oder R<sup>7</sup> und R<sup>8</sup> zusammen mit dem benachbarten Stickstoffatom einen 3- bis 8-gliedrigen heterocyclischen Ring bilden).
3. Medikament umfassend ein 4-Hydroxy-4-phenylpiperidin-Derivat oder ein Salz desselben gemäß Anspruch 1 oder 2 als Wirkstoff.
4. Das Medikament gemäß Anspruch 3, das ein peripheres Analgetikum ist.
5. Pharmazeutische Zusammensetzung umfassend ein 4-Hydroxy-4-phenylpiperidin-Derivat oder ein Salz desselben gemäß Anspruch 1 oder 2 und einen pharmazeutisch unbedenklichen Träger.



6. Verwendung eines 4-Hydroxy-4-phenylpiperidin-Derivats oder eines Salzes desselben gemäß Anspruch 1 oder 2 zur Herstellung eines Medikaments zur Schmerzbehandlung.
7. Verwendung gemäß Anspruch 6, wobei das Medikament ein peripheres Analgetikum ist.

# Revendications

1. Dérivé de la 4-hydroxy-4-phénylpipéridine représenté par la formule (1) suivante :



(1)

[dans laquelle,

R<sup>1</sup> et R<sup>2</sup> sont identiques ou différents et chacun indépendamment représente

un atome d'hydrogène,  
un groupe alkyle en C<sub>1-6</sub> ou  
un groupe cycloalkyle, ou

R<sup>1</sup> et R<sup>2</sup> peuvent former

un cycle pyrrolidinyle conjointement avec l'atome d'azote adjacent,

R<sup>3</sup> représente

un atome d'hydrogène ou  
un groupe (CR<sup>4</sup>R<sup>5</sup>)<sub>n</sub>-Y  
(dans lequel,

R<sup>4</sup> et R<sup>5</sup> représentent chacun

un atome d'hydrogène ou  
un groupe alkyle en C<sub>1-6</sub>,

Y représente un groupe

-COOR<sup>6</sup>, -CONR<sup>7</sup>R<sup>8</sup>, -OR<sup>9</sup> ou -OCOR<sup>10</sup>  
(dans lequel

R<sup>6</sup>, R<sup>9</sup> et R<sup>10</sup> chacun indépendamment représente

un atome d'hydrogène,  
un groupe alkyle en C<sub>1-6</sub> ou  
un groupe cycloalkyle,

R<sup>7</sup> et R<sup>8</sup> sont identiques ou différents  
et chacun indépendamment représente

un atome d'hydrogène,  
un groupe alkyle en C<sub>1-6</sub> ou  
un groupe cycloalkyle ou

5 R<sup>7</sup> et R<sup>8</sup> peuvent former un groupe hétéro-cyclique conjointement avec l'atome d'azote adjacent),  
et

n représente 1 à 6)),

10 ou sel de celui-ci.

2. Composé selon la revendication 1, pour lequel R<sup>1</sup> et R<sup>2</sup> sont identiques ou différents et chacun indépendamment  
représente un atome d'hydrogène, un groupe alkyle en C<sub>1-6</sub> ou un groupe cycloalkyle en C<sub>3-8</sub>, ou R<sup>1</sup> et R<sup>2</sup> peuvent  
former, conjointement avec l'atome d'azote adjacent, un groupe hétérocyclique pyrrolidinyle, R<sup>3</sup> représente un  
15 atome d'hydrogène ou un groupe -(CR<sup>4</sup>R<sup>5</sup>)<sub>n</sub>-Y (dans lequel R<sup>4</sup> et R<sup>5</sup> représente chacun un atome d'hydrogène  
ou un groupe alkyle en C<sub>1-6</sub>, Y représente un groupe -COOR<sup>6</sup>, -CONR<sup>7</sup>R<sup>8</sup>, -OR<sup>9</sup> ou -OCOR<sup>10</sup> (dans lequel R<sup>6</sup>,  
R<sup>9</sup> et R<sup>10</sup> représentent chacun indépendamment un atome d'hydrogène, un groupe alkyle en C<sub>1-6</sub> ou un groupe  
cycloalkyle en C<sub>3-8</sub>, R<sup>7</sup> et R<sup>8</sup> sont identiques ou différents et chacun indépendamment représente un atome d'hy-  
drogène, un groupe alkyle en C<sub>1-6</sub> ou un groupe cycloalkyle en C<sub>3-8</sub> ou R<sup>7</sup> et R<sup>8</sup> peuvent former conjointement  
20 avec l'atome d'azote adjacent un groupe hétérocyclique à 3 à 8 chaînons).

3. Médicament comprenant un dérivé de la 4-hydroxy-4-phénylpipéridine ou un sel de celui-ci tel que revendiqué  
dans la revendication 1 ou 2 en tant qu'ingrédient actif.

25 4. Médicament selon la revendication 3, qui est un analgésique périphérique.

5. Composition pharmaceutique comprenant un dérivé de la 4-hydroxy-4-phénylpipéridine ou un sel de celui-ci tel  
que revendiqué dans la revendication 1 ou 2 et un véhicule pharmaceutiquement acceptable.

30 6. Utilisation d'un dérivé de la 4-hydroxy-4-phénylpipéridine ou d'un sel de celui-ci tel que revendiqué dans la reven-  
dication 1 ou 2 pour la préparation d'un médicament pour le traitement de la douleur.

7. Utilisation selon la revendication 6, ledit médicament étant un analgésique périphérique.

35

40

45

50

55